Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Ozanimod as induction and maintenance therapy for ulcerative colitis
True North Study Group
Icahn School of Medicine at Mount Sinai
Marc and Jennifer Lipschultz Precision Immunology Institute
Medicine
Medicine - Gastroenterology
Research output
:
Contribution to journal
›
Article
›
peer-review
265
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ozanimod as induction and maintenance therapy for ulcerative colitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ulcerative Colitis
100%
Induction Therapy
100%
Maintenance Therapy
100%
Ozanimod
100%
Placebo
57%
Clinical Response
14%
Active Ulcerative Colitis
14%
Clinical Remission
14%
Maintenance Interval
14%
Induction Period
14%
Histologic
7%
Randomized Placebo-controlled Trial
7%
Serious Infection
7%
Once-daily
7%
Inflammatory Bowel Disease
7%
Mayo Score
7%
Daily Dose
7%
Infection Rate
7%
Aminotransferase Levels
7%
Sphingosine-1-phosphate Receptor (S1PR)
7%
Hydrochloride
7%
Hierarchical Testing
7%
Liver Aminotransferase
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
100%
Ozanimod
100%
Placebo
64%
Infection
14%
Remission
14%
Inflammatory Bowel Disease
7%
Aminotransferase
7%
Sphingosine 1 Phosphate Receptor
7%
Immunology and Microbiology
Ulcerative Colitis
100%
Ozanimod
100%
Inflammatory Bowel Disease
7%